13F Pro quality score
Rank #2,739 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reported revenue, net income and operating margin by fiscal year, from Neuphoria Therapeutics Inc.'s annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2026 | 10-K | $1.2M | $-13.5M | — |
| FY 2025 | 10-K | $15.6M | $-369.6K | -7.2% |
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
Neuphoria Therapeutics Inc. (NEUP) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NEUP at 21.0/100 on a composite quality score built from its SEC filings, placing it at rank #2,739 of 2,925 stocks — the bottom half of the AI-ranked universe. Top institutional holders of NEUP by reported 13-F value include Lynx1 Capital Management, AdvisorShares Investments, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. NEUP trades on the Nasdaq exchange and files with the SEC under CIK 1191070. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NEUP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Neuphoria Therapeutics Inc. directly from SEC EDGAR.
Financials through the period ended SEC EDGAR: CIK 1191070 →